Showing 5391-5400 of 8841 results for "".
- USPTO Grants Patents to TOOsonix A/S for HIFU Technologies in Dermatologyhttps://practicaldermatology.com/news/uspto-grants-patents-to-toosonix-as-for-hifu-technologies-in-dermatology/2461420/The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual prop
- IFPA Launches All the Colors We Are to Call Attention to Diversity in Psoriatic Diseaseshttps://practicaldermatology.com/news/ifpa-launches-all-the-colors-we-are-to-call-attention-to-diversity-in-psoriatic-diseases/2461419/IFPA is launching a new image library that raises awareness of diversity in psoriatic disease. IFPA is the global organization representing all people with psoriatic disease,. Go to any image database, and type “psoriasis” in the search bar. The results? Invariably
- November is Hyperhidrosis Awareness Monthhttps://practicaldermatology.com/news/november-is-hyperhidrosis-awareness-month-1/2461411/November is Hyperhidrosis Awareness Month and the
- Monkeypox Update: Kids Aged 8 or Younger at High Risk for More Severe Monkeypoxhttps://practicaldermatology.com/news/monkey-pox-update-kids-aged-8-or-younger-at-high-risk-for-more-severe-monkeypox/2461409/Children aged 8 years or younger are at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal. Young children would be a key target group for smallpox vaccination and other urgent measures if the outbreak widens, according to the review b
- Hair Straightening Chemicals Associated with Higher Uterine Cancer Riskhttps://practicaldermatology.com/news/hair-straightening-chemicals-associated-with-higher-uterine-cancer-risk/2461397/Chemical hair straighteners may be contributing to a rise in aggressive uterine cancers a new study in the Journal of the National Cancer Institute suggests. The
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- #NationalMenopauseDay Launch: VICHY Laboratoires Introduces Neovadiol Meno 5 Serumhttps://practicaldermatology.com/news/national-menopause-day-launch-vichy-laboratoires-introduces-neovadiol-meno-5-serum/2461388/VICHY Laboratoires is launching
- ASDS News: CellFX Clears Low-Risk Basal Cell Carcinoma Lesionshttps://practicaldermatology.com/news/asds-news-cellfx-clears-low-risk-basal-cell-carcinoma-lesions/2461374/CellFX procedure is effective for low-risk superficial and nodular basal cell carcinoma lesion clearance, according to research presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. "It is exciting and encouraging to see complete clearance of b
- Spotlight On: Honey and Its Role in Wound Healinghttps://practicaldermatology.com/news/spotlight-on-honey/2461353/Honey may play a role in wound healing due to its antimicrobial and tissue-regenerative properties, according to scientists from the University of Manchester. Their review of more than 250 articles spans 85 years -with oldest article from 1937- is published in the journal Pharmaceu
- Almirall's Tildrakizumab Demonstrates Meaningful Sleep Improvement in People Living with Psoriasishttps://practicaldermatology.com/news/almiralls-tildrakizumab-demonstrates-meaningful-sleep-improvement-in-people-living-with-psoriasis/2461345/During the 31st EADV (European Association of Dermatology and Venereology) Congress, Almirall S.A shared the results from TRIBUTE, an interventional phase IV clinical study that resembled real-life clinical practice. In this study, Ilumetri (tildrakizumab) is&n